Are Divis Laboratories Ltd latest results good or bad?

Feb 11 2026 07:29 PM IST
share
Share Via
Divi's Laboratories Ltd reported mixed results for Q3 FY25, with a 4.09% sequential decline in net sales to ₹2,604 crores but a 12.29% year-on-year growth. While operating efficiency improved, net profit fell 15.38% sequentially, raising concerns about long-term growth sustainability despite a strong balance sheet.
Divi's Laboratories Ltd has reported its financial results for the quarter ending December 2025, highlighting a complex operational landscape. The company recorded net sales of ₹2,604 crores, reflecting a sequential decline of 4.09% from ₹2,715 crores in the previous quarter, although this represents a year-on-year growth of 12.29% compared to ₹2,319 crores in the same quarter last year. This sequential revenue contraction suggests some volatility in order flows and customer demand patterns typical of the API manufacturing business.
In terms of profitability, the net profit for the quarter was ₹583 crores, which indicates a significant sequential decline of 15.38% from ₹689 crores in the prior quarter, and a slight year-on-year contraction of 1.02% from ₹589 crores in Q3 FY25. This decline in net profit occurred despite an increase in operating profit, which reached ₹890 crores, the highest in recent periods, suggesting that the profit pressure stemmed from factors beyond core operations. The operating margin, excluding other income, improved to 34.18% from 32.71% in the previous quarter, indicating strong operational efficiency and cost management. However, the profit after tax (PAT) margin contracted to 22.39% from 25.38%, primarily due to lower other income and a normalization of the tax rate. Divi's Laboratories continues to demonstrate strong operational metrics, with an average return on equity (ROE) of 17.24%, reflecting good capital efficiency. However, the company faces challenges with a long-term growth trajectory, as evidenced by a five-year sales growth rate of 9.86% and EBIT growth of 5.38%, which raises concerns about the sustainability of its premium valuation multiples. The company has maintained a strong balance sheet with zero long-term debt, indicating financial flexibility. However, the recent performance has led to an adjustment in its evaluation, reflecting the mixed operational trends and market conditions. Overall, while Divi's Laboratories showcases operational excellence with high margins and a solid balance sheet, the recent financial results highlight underlying growth concerns and the challenges of maintaining its premium valuation amidst a competitive and cyclically pressured industry landscape.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News